4th Jun 2018 11:11
LONDON (Alliance News) - Biopharmaceutical company Hutchison China MediTech Ltd said Monday patients in its FRESCO Phase III study "demonstrated a statistically significant and clinically meaningful benefits".
Speaking at the 2018 American Society of Clinical Oncology Annual Meting held in Chicago, US from last Friday to Tuesday, Hutchison China said fruquintinib offered benefits to third-line metastatic colorectal cancer patients in China.
Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors 1,2 and 3.
The results presented "showed that the benefits of fruquintinib were generally consistent across all subgroups".
Out of a total of 278 fruquintinib-treated patients, 111 received prior target therapy. Of those, fruquintinib "significantly prolonged" overall survival to 7.69 months from 5.98 and progression-free survival to 3.65 months from 1.84 months when compared to the placebo.
This new dataset is part of the new drug application filed and accepted by the China National Drug Administration. Hutchison China are carrying out additional clinical trials in China for lung cancer and gastric cancer.
Shares in Hutchison China MediTech were down 1.7% Monday at 4,099.75 pence each.
Related Shares:
Hutchmed